Elanco Announces Comprehensive Antibiotic Stewardship Plan, Significant Research Effort

GREENFIELD, Ind., June 2, 2015 -- Today, Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY), will participate in the White House Forum on Antibiotic Stewardship where Elanco President Jeff Simmons will participate in a panel discussion. Concurrently, Simmons is unveiling the company's multi-faceted approach to combat the growing concern about antibiotic resistance. A summary of Simmons' remarks follows:

In the next few decades, demand for animal protein will climb 60 percent[1] as population increases and the global middle class expands by three billion people[2]. These numbers are important, because we're already overusing the Earth's resources, consuming about 1.5 times the natural resources we should use in a year[3]. Delivering safe, sufficient, affordable protein to feed the growing population has never been at greater risk.

The welfare of animals we rely upon to provide protein is also at risk. Today, we have emerging diseases on every continent, including the extreme of avian influenza right here in the United States. Beyond that – nearly 3 in 4 cattle experience symptoms of respiratory disease[4] at some point in their life and 1 in 6 dairy cattle experience mastitis[5] in their productive life. It is our industry's responsibility to keep animals healthy and treat the ones that get sick while safeguarding antibiotics for future generations through responsible use. Ultimately, this is about One Health – not just animal health, but this work creates healthy food, ensures the health of people and protects the planet. 

Elanco has committed to an eight-step antibiotic stewardship plan that ensures the responsible use of antibiotics, reduces shared-class antibiotic use and replaces antibiotics with alternatives.

Elanco's Eight-Step Antibiotic Stewardship Plan

  1. Act with responsibility globally - not just according to U.S. regulation - by working with food producers and retailers to provide training and encourage policies that reduce shared-class antibiotic use and increase veterinarian oversight.

  2. Cease marketing of growth promotion uses for shared-class antibiotics and complete full regulatory change to end growth promotion use of shared-class antibiotics globally by the end of 2016.

  3. Help customers eliminate continuous use of shared-class antibiotics for therapy purposes by providing an alternative.

  4. Eliminate over-the-counter sales of shared-class antibiotics globally - including injectable products - where veterinarian oversight exists.

  5. Eliminate concurrent use of shared-class antibiotics to treat the same disease.

  6. Support veterinary oversight and responsible use, including helping build infrastructure globally.

  7. Develop new animal-only antibiotics. No animal should ever be treated with a shared-class antibiotic if an animal-only option exists. Animal-only antibiotics optimize animal welfare without compromising human use antibiotics.

  8. Create alternatives. Elanco commits to invest two-thirds of our food animal research budget to quickly evaluate 25 candidates and deliver 10 viable non-antibiotic development projects that address diseases where there are few, or no, alternatives to shared-class antibiotics. (Respiratory disease and enteric disease in cattle, swine and poultry and mastitis in cattle.)

In one year, Elanco will host an animal health accountability summit to provide a progress report on our effort to deliver non-antibiotic alternatives. Along the way, we will collaborate with customers, academics and appropriate regulatory authorities, which will include establishing an expert advisory panel. Finally, Elanco will collaborate with our industry association and other technology companies to advance this effort as quickly as possible.

It is important that we don't enact regulations or policies that move faster than available science, which could jeopardize animal health as well as food safety and food security. Setting timelines without solutions could be dangerous, compromising animal welfare. Policies that require complete elimination of all antibiotics in animal production aren't right for the animal and they aren't right for the consumer either. We must take a pragmatic approach that doesn't put animals at risk.

This is a challenging endeavor not without risk, but with intentional focus, dedicated investment and collaboration from an event like today, we believe we can make a difference, shaping a positive future with better health outcomes for people and animals.

About Elanco 
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for nearly 7,000 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. Visit us at Elanco.com and EnoughMovement.com.